UNASSIGNED: In anecdotal reports, some @entity1 with @entity3039 ( @entity3039 ) maintained platelet counts after discontinuing @entity31799 . Here, we examined rates of platelet response (>= 50  *  10(9) /l), remission, splenectomy and adverse events in @entity1 with primary @entity3039 duration  <=6  months who were treated with @entity31799 for  <=12  months. The starting dose of @entity31799 was 1   g/kg; concomitant and rescue treatments were permitted to maintain platelet counts. @entity1 with platelet counts >= 50  *  10(9) /l at the end of 12  months entered a dose taper in which the @entity31799 dose was decreased as long as platelet counts were maintained. Remission (platelet count >= 50  *  10(9) /l for 24 consecutive weeks with no @entity3039 treatments) was evaluated in @entity1 once @entity31799 was discontinued. Over the 12  months, a high response rate (>90%) was observed. Platelet response occurred quickly (median, ~2  weeks) and was observed for a cumulative median of 11  months. Remission was observed in 24 @entity1 (32%); there were no significantly predictors of remission. Most (20/24) @entity1 had remission start before the forced taper. No new safety signals were identified. Thus, in @entity1 with early-stage @entity3039 , @entity31799 was well tolerated and induced rapid responses, with remission occurring in approximately one-third of @entity1 (NCT01143038, Amgen 20080435).

Remission and platelet responses with @entity31799 in primary XXXX : final results from a phase 2 study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity3039 :: ('MESH:D016553', 'Disease') :: ['ITP', 'immune thrombocytopenia'] @entity31799 :: ('MESH:C488777', 'Chemical') :: ['romiplostim']
@entity3039 :: (MESH:D016553,Disease) :: ['immune thrombocytopenia']
